ClinicalTrials.gg
RecruitingNCT04562623GYNECO-IMM&COUpdated Apr 27, 2026

Prospective Study of Immune Alterations in Operable Breast and Ovarian Carcinoma

An observational study in Ovarian Carcinoma and Breast Carcinoma, sponsored by Centre Leon Berard. Recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by Centre Leon Berard · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jul 2021; still recruiting 5 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
160
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 291 studies in Ovarian Neoplasms with a site in France — 63 open to participants now, 103 under way, 25 of them phase 3. Ovarian Neoplasms · France.

Planned enrollment
27th of 44
160 · median 232
Started
2021
with 22 others
Observational
44 of 291
9 open now
Primary completion
2026-07
later than 20 of 102 live
Registered
191st of 291
by date

Among the 291 studies in Ovarian Neoplasms with a site in France, this one is the 27th largest by planned enrollment of the 44 observational ones that give a count, is one of 23 that started in 2021, is one of 44 observational ones, reaches primary completion later than 20 of the 102 other live ones, and was the 191st registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

63 of the 291 studies in Ovarian Neoplasms with a site in France are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 291 studies in Ovarian Neoplasms with a site in France, or all of them as a file.
02

Study summary

GYNECO-IMM\&Co is a prospective clinical and biological cohort ; this study aims to identify immune surveillance and escape mechanisms and also predictive biomarkers for survival patients who suffer from ovarian and breast carcinoma.

Read the detailed description

Breast cancer is the main cancer in women and is the second cause of mortality by cancer in the world for women ; high grade serous ovarian cancer is a rare pathology but survival is less 25% at 5 years.

Breast and ovarian cancers are complex entities with heterogeneous tumor cells but also normal cells including immune cells with represent the microenvironment of the tumor.This microenvironment limits tumor progression but also has been shown to play a crucial role in disease progression, tumor angiogenesis, maintenance and resistance to anticancer therapies.

Despite newly developed immunotherapies, only one-third of patients with breast and ovarian cancer responds to checkpoint inhibitors ; so today there is poor benefit to treat breast and ovarian cancers with immunotherapies. Therefore it needs to better understand immune mechanisms which reduce treatment efficacy. The aim of this clinical study is to better understand mechanisms of immune response inhibition in breast and ovarian cancers. It would characterize actionable targets in patients with resistance to conventional anticancer treatments or immunotherapies.In this context, the hypothesis is that some specific phenotypical or functional alterations of specific immune cells populations (DC, LB, plasmocytes IgA, neutrophils, NK cells, CD8+CD39+ LT, Treg) induce tumoral progression in breast and ovarian cancer. These immune populations will be described (qualitative, quantitative and functional descriptions ; proteic, transcriptomic and genomic profiles) in order to i) determine new immune surveillance mechanisms ii) new targets which allow efficient antitumoral immunity in breast and ovarian cancers.

03

Conditions studied

  • Ovarian Carcinoma
  • Breast Carcinoma

Keywords

  • Ovarian cancer
  • Breast cancer
  • Immune alterations
  • Predictive biomarkers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult female patients with operable ovarian or breast cancer : patients with high grade serous ovarian carcinoma (cohort A), Breast carcinoma SBR grade II or III > 3 cm (cohort B), Extended breast carcinoma In situ associated with invasive nodule carcinoma macroscopically visible and eligible to mastectomy (cohort C).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • I1. Female patients aged ≥ 18 tears at time of inform consent signature.
  • I2. Patient with planned primitive tumor surgery listed below : High grade serous ovarian carcinoma (cohort A), Breast carcinoma SBR grade II or III > 3 cm (cohort B), Extended breast carcinoma In situ associated with invasive nodule carcinoma macroscopically visible and eligible to mastectomy (cohort C).

Note : Patients previously treated by chemotherapy are eligible and all chemotherapies are authorized.

  • I3. Patient should understand, sign, and date the written voluntary form prior to any protocol-specific procedures and should be willing to comply procedures required per protocol.
  • I4. Patient must be covered by a medical insurance.

Exclusion criteria

Exclusion Criteria:

  • E1. Patient under guardianship or trusteeship.
  • E2. Cancer with constitutional BRCA1/2 mutation.
  • E3. Previously treated by immunomodulators (PD1/PDL1, CTLA4).
  • E4. Systemic treatment by an immunosuppressor (including, but not limited to, , azathioprine, methotrexate, thalidomide and anti-TNF-alpha) or by an immunostimulant within 2 weeks before inclusion, except corticosteroids listed below: inhaled corticosteroids, intranasal corticosteroids, topic corticosteroids, and systemic corticosteroids with prednisone or equivalent physiological dose ≤ 10 mg/day.
  • E5. Patient with known history of disease including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis,systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipids syndrome, Wegener syndrome , Sjögren syndrome, Guillain-Barré syndrome, multiple sclerosis, vascularitis, or glomerulonephritis, B or C hepatitis infection, infection.
  • E6. Patient with other active tumor except if the tumor is considered not to interfere with outcome measures following sponsor approval such as basal or squamous cell skin cancer. Patient previously treated for an other cancer and without relapse for at least one year are eligible.
  • E7. Pregnant or breastfeeding woman.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
160 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Cohort A : High grade serous ovarian carcinoma
  • Cohort B :Breast carcinoma SBR grade II or III

    Breast carcinoma SBR grade II or III superior to 3 cm

  • Cohort C : Extended Breast carcinoma In situ

    Extended Breast carcinoma In situ associated with invasive nodule carcinoma macroscopically visible and eligible to mastectomy

06

What researchers measure

Primary outcomes

  1. Characterization of immune cells populations on tumour sample from exeresis

    Frequency, phenotype and function/activation status of immune cells will be determined by flow cytometry, electrochemiluminescence and proliferation test

    Time frame: At surgery

Secondary outcomes

  1. Characterization of immune cells populations on blood sample

    Frequency, phenotype and function/activation status of immune cells will be determined by flow cytometry and electrochemiluminescence

    Time frame: At surgery

  2. Characterization of transcriptomic profile of immune cells populations

    Biomarkers expression, activation or inhibition of functional pathways will be determined by transcriptome sequencing (RNAseq and single cell RNAseq) on tumor sample

    Time frame: At surgery

  3. Characterization of molecular profile of tumor sample

    Genes profile (Mutation, amplification, insertion, deletion) will be determined by whole exome sequencing (WES)

    Time frame: At surgery

  4. Comparison of soluble factors of the tumor microenvironment with soluble factors present in the blood

    Comparative characterization (nature and concentration) by Luminex technology MSD

    Time frame: At surgery

  5. Characterization of immunoglobulins and their antigenic targets

    Characterization by Elisa and Luminex

    Time frame: At surgery

  6. Characterization of TCR repertory of LT CD8+ and Tregs

    TCR repertory of LT CD8+ and Tregs will be determined by transcriptomic profile by RNAseq

    Time frame: At surgery

  7. Determination of the correlation between biological characterizations at surgery and clinical characterizations

    Clinical characterizations are consistent with treatment response and survival ; biological characteristics will describe molecular and transcriptomic profile of the tumor.

    Time frame: Up to 60 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Jul 2026, 60 months after the start.

Of 216 non-industry observational studies under Ovarian Neoplasms, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 206. This study's planned 60 months is below that.

Counting every sponsor, half of 268 studies reached it within 61 months; a quarter within 35 and three quarters within 185.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2020
First posted
Sep 24, 2020
StartActual
Jul 1, 2021
Primary completionEst.
Jul 2026
CompletionEst.
Jul 2031
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04562623
Lead sponsor
Centre Leon Berard
Collaborators
Cancer Research Center of Lyon
Responsible party
Sponsor
First posted
Sep 24, 2020
Start date
Jul 1, 2021
Primary completion
Jul 2026 (estimated)
Completion
Jul 2031 (estimated)
Last update
Apr 27, 2026

Study contacts

Nicolas Chopin
Contact
nicolas.chopin@lyon.unicancer.fr
+ 33 (0)4 78 78 28 28
Christophe Caux
Contact
Christophe.caux@lyon.unicancer.fr
+ 33 (0)4 78 78 27 50

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion